QIAGEN and Element Biosciences announced a strategic partnership to offer comprehensive next-generation sequencing workflows for the Element AVITI System, an innovative sequencing platform. Element’s AVITI System is a versatile benchtop sequencer offering a combination of performance, cost, and flexibility for a wide range of NGS applications. “The collaboration between QIAGEN and Element Biosciences delivers unprecedented insights across various genomic applications to our customers worldwide. Researchers are increasingly searching for complete solutions and workflows from sample to insight, and we are committed to advancing the field together by providing innovative technology and applications that help researchers accelerate discovery,” said Nitin Sood, Senior Vice President, Head of Life Sciences Business Area at QIAGEN.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QGEN:
- Qiagen price target lowered to $46 from $50 at Baird
- Qiagen backs FY23 sales view of at least $1.97B, consensus $1.97B
- Qiagen reports Q3 EPS 50c, consensus 48c
- QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER
- Qiagen (QGEN) Q3 Earnings Cheat Sheet
